Insider · CIK 0001697779
Chuck Ence
Files at RLMD (RELMADA THERAPEUTICS, INC.). First filing May 20, 2025, latest Nov 6, 2025.
In brief
Chuck Ence files SEC Form 4 as COO at RLMD (RELMADA THERAPEUTICS, INC.). Since May 20, 2025, Chuck Ence has reported 2 open-market buys worth $403k and 0 open-market sells worth $0, the latest filed on Nov 6, 2025.
A track record needs three past buys with six months of prices behind them; Chuck Ence has 0, so none is measured yet.
The newest scored trade: bought $299k of RLMD on Nov 5, 2025, filed Nov 6, 2025, scored 63 (notable). In the last 12 months: 1 buy worth $299k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RLMD: RELMADA THERAPEUTICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 63Notable | RELMADA THERAPEUTICS, INC. | $299k 136,000 shares | +51% | +896% from low-26% from high | |
| 58Moderate | RELMADA THERAPEUTICS, INC. | $103k 228,961 shares | +588% | +83% from low-87% from high |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | RLMD RELMADA THERAPEUTICS, INC. | AGrant or award Stock Appreciation Rightsderivative | +828,000 | $0.00 | $0 | 828,000 | Dec 16, 2025 |
| Nov 5, 2025 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +136,000 | $2.20 | $299k | 403,931 | Nov 6, 2025 |
| Jun 26, 2025 | RLMD RELMADA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Jun 30, 2025 |
| May 16, 2025 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +228,961 | $0.45 | $103k | 267,931 | May 20, 2025 |
| Dec 15, 2023 | RLMD RELMADA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +82,090 | $0.00 | $0 | 82,090 | Dec 19, 2023 |
Questions about Chuck Ence
Answered from the filings on this page, as of the latest one.
Is Chuck Ence buying or selling?
In the last 12 months Chuck Ence reported 1 open-market buy worth $299k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $299k of RLMD on Nov 5, 2025. Grants, option exercises and tax withholding are not counted.
How did Chuck Ence's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Chuck Ence has 0.
Where does Chuck Ence file Form 4?
Chuck Ence has filed Form 4 at RLMD (RELMADA THERAPEUTICS, INC.) as Chief Accounting and CO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.